Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
IMS 2022
;
Have you watched our MDS session w/ @Dr_AmerZeidan, Rena Buckstein, @garciamanero & @andrewbrunner yet?🤔🎥
Click here to gain valuable insight into the practical considerations when treating pts with LR-MDS, including some common pitfalls:
👉 https://ow.ly/8MiG50Suu9T 👈
#MDSsm
Watch our excellent interview with Manali Kamdar (@mana1981) of @CUCancerCenter to hear the findings of subgroup analyses of the TRANSCEND-NHL-001 trial #MantleCellLymphoma cohort!
Click here:
👉
#LYMsm #CTSM #ImmunoOnc #HemOnc #EHA2024 @EHA_Hematology
Subgroup analyses of the TRANSCEND-NHL-001 MCL cohort: the effect of prior LOT & BTKi refractoriness
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, presents the findings of post-hoc subgroup analys...
ow.ly
Tagraxofusp, a first‐in‐class #CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature - Jen - 2024 - Cancer | @jenweiying @mkonople @doctorpemm #endcancer #BPDCN @JournalCancer
Check out this week's podcast, where you'll learn about the role of BTK inhibitors in the treatment of mantle cell lymphoma, directly from leading experts! 🎧🩸
Listen here:
#LymSM #HemOnc
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 |...
Tune in to this week's VJHemOnc podcast which covers the evolving role of BTK inhibitors in the treatment of mantle cell lymphoma (MCL).
ow.ly
The 1st MPN Workshop of the Carolinas will take place next month in Asheville, NC and online! With a fantastic agenda, it is not one to be missed!
Register here to attend virtually or in person:
👉 https://ow.ly/bGFN50SHUQG 👈
#MPNsm #HemOnc #MPNWorkshopNC @levinecancer @spahec
IMS 2022
Have you watched our MDS session w/ @Dr_AmerZeidan, Rena Buckstein, @garciamanero & @andrewbrunner yet?🤔🎥
Click here to gain valuable insight into the practical considerations when treating pts with LR-MDS, including some common pitfalls:
👉 https://ow.ly/8MiG50Suu9T 👈
#MDSsm
Watch our excellent interview with Manali Kamdar (@mana1981) of @CUCancerCenter to hear the findings of subgroup analyses of the TRANSCEND-NHL-001 trial #MantleCellLymphoma cohort!
Click here:
👉
#LYMsm #CTSM #ImmunoOnc #HemOnc #EHA2024 @EHA_Hematology
Subgroup analyses of the TRANSCEND-NHL-001 MCL cohort: the effect of prior LOT & BTKi refractoriness
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, presents the findings of post-hoc subgroup analys...
ow.ly
Tagraxofusp, a first‐in‐class #CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature - Jen - 2024 - Cancer | @jenweiying @mkonople @doctorpemm #endcancer #BPDCN @JournalCancer
Check out this week's podcast, where you'll learn about the role of BTK inhibitors in the treatment of mantle cell lymphoma, directly from leading experts! 🎧🩸
Listen here:
#LymSM #HemOnc
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 |...
Tune in to this week's VJHemOnc podcast which covers the evolving role of BTK inhibitors in the treatment of mantle cell lymphoma (MCL).
ow.ly
The 1st MPN Workshop of the Carolinas will take place next month in Asheville, NC and online! With a fantastic agenda, it is not one to be missed!
Register here to attend virtually or in person:
👉 https://ow.ly/bGFN50SHUQG 👈
#MPNsm #HemOnc #MPNWorkshopNC @levinecancer @spahec
